

117TH CONGRESS  
1ST SESSION

# S. 1604

To codify the successes of rapid development of safe vaccines through Operation Warp Speed, for the next administration to use as a guide in the event of another pandemic.

---

IN THE SENATE OF THE UNITED STATES

MAY 13, 2021

Mr. COTTON introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To codify the successes of rapid development of safe vaccines through Operation Warp Speed, for the next administration to use as a guide in the event of another pandemic.

1       *Be it enacted by the Senate and House of Representa-  
2 tives of the United States of America in Congress assembled,*

**3 SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Operation Warp Speed  
5 Act of 2021”.

**6 SEC. 2. FINDINGS.**

7       Congress finds as follows:

1                         (1) COVID–19 has infected more than  
2                         32,000,000 people in the United States and taken  
3                         the lives of more than 550,000.

4                         (2) The Trump Administration’s creation of  
5                         Operation Warp Speed, on May 15, 2020, and the  
6                         development of 3 COVID–19 vaccines, in less than  
7                         a year, was the greatest success in getting the  
8                         COVID–19 pandemic under control, and one of the  
9                         greatest public health programs in history.

10                         (3) As a result of the Trump Administration’s  
11                         partnership with the private sector, more than  
12                         150,000,000 doses of authorized vaccines have been  
13                         administered in the United States.

14                         (4) The unprecedented rapid deployment of  
15                         COVID–19 vaccines and therapeutics, thanks to the  
16                         public-private partnership of Operation Warp Speed,  
17                         has helped the United States combat the spread of  
18                         COVID–19, protect at-risk populations, save millions  
19                         of lives, and return to normal life.

20 **SEC. 3. CODIFYING SUCCESSES.**

21                         (a) ADDRESSING THE STRATEGIC NATIONAL STOCK-  
22                         PILE.—

23                         (1) ANNUAL THREAT-BASED REVIEW.—In con-  
24                         ducting the annual threat-based review with respect  
25                         to the Strategic National Stockpile under section

1       319F–2(a)(2)(A) of the Public Health Service Act  
2       (42 U.S.C. 247d–6b(a)(2)(A)), the Secretary of  
3       Health and Human Services (referred to in this sec-  
4       tion as the “Secretary”) shall ensure that such re-  
5       view considers, and the report to Congress includes,  
6       information about the supply levels in such stockpile  
7       and any materials that may be missing. The review  
8       described in the previous sentence shall include a  
9       supply chain assessment of materials in the Stra-  
10      tegic National Stockpile that considers whether the  
11      United States could procure such materials in the  
12      event of a pandemic that limits trade and access to  
13      international supply chains.

14                     (2) PROCURING SUPPLIES FOR THE SNS.—In  
15       procuring supplies for the Strategic National Stock-  
16       pile under section 319F–2(a) of the Public Health  
17       Service Act (42 U.S.C. 247d–6b(a)), the Secretary  
18       shall—

19                             (A) give priority to manufacturers of such  
20       supplies, including vaccines, that are manufac-  
21       tured by companies located in the United  
22       States;

23                             (B) in the case that no domestic manufac-  
24       turer is available for certain supplies, including  
25       vaccines, assess ways to ramp up domestic

1           manufacturing of such supplies, including vac-  
2           cines; and

3           (C) in the case that no domestic manufac-  
4           turer is available for certain supplies, including  
5           vaccines, and it is determined that domestic  
6           manufacturing cannot be ramped up in an ap-  
7           propriate amount of time, give priority to com-  
8           panies that are located in countries other than  
9           the People’s Republic of China.

10          (b) INCREASING SPEED FOR SAFE EUA.—Section  
11        564 of the Federal Food, Drug, and Cosmetic Act (21  
12        U.S.C. 360bbb–3) is amended—

13           (1) in subsection (c)—

14           (A) in the matter preceding paragraph  
15           (1)—

16           (i) by inserting “the Commissioner of  
17           Food and Drugs,” before “the Assistant  
18           Secretary for”; and

19           (ii) by striking “the Secretary con-  
20           cludes” and inserting “not fewer than 3 of  
21           such Commissioner, such Assistant Sec-  
22           retary, and such Directors, vote in favor of  
23           such authorization after concluding”;

24           (B) in paragraph (4), by striking “; and”  
25           and inserting a semicolon;

(C) by redesignating paragraph (5) as paragraph (6); and

5               “(5) that the product complies with standards  
6 for clinical trials established by the Secretary, in  
7 consultation with such Commissioner, such Assistant  
8 Secretary, and such Directors; and”; and

9 (2) by adding at the end the following:

10        "(n) CONSIDERATION OF DATA.—The Secretary, and  
11 the heads of agencies described in subsection (c), shall  
12 consider the data submitted with respect to a product for  
13 which authorization is being sought under this section, on  
14 a rolling basis, as such data becomes available to such Sec-  
15 retary and heads of agencies.".

16 (c) GAPS IN CLINICAL TRIALS.—The Director of the  
17 National Institutes of Health shall assess any geographical  
18 gaps in clinical trial sites for drugs or biological products  
19 and shall develop a plan for increasing the number of such  
20 sites across broad geographic areas.

21 (d) REQUIRING ASPR TO IMPROVE MANUFAC-  
22 TURING CAPABILITIES UNDER CONDITIONS OF PRES-  
23 SURE —

24                             (1) VACCINE PRODUCTION.—The Secretary is  
25                             authorized to use amounts made available to the De-

1       partment of Health and Human Services for pur-  
2       poses of producing vaccines in response to a public  
3       health emergency prior to emergency use authoriza-  
4       tion of such vaccine under section 564 of the Fed-  
5       eral Food, Drug, and Cosmetic Act (21 U.S.C.  
6       360bbb–3) or licensure of such vaccine under section  
7       351 of the Public Health Service Act (42 U.S.C.  
8       262).

9                     (2) OPERATION WARP SPEED DIRECTOR.—Sec-  
10          tion 2811 of the Public Health Service Act (42  
11          U.S.C. 300hh–10) is amended by adding at the end  
12          the following:

13          “(g) OPERATION WARP SPEED DIRECTOR.—There is  
14          established within the Office of the Assistant Secretary for  
15          Preparedness and Response an Office of Operation Warp  
16          Speed, for purposes of responding to public health emer-  
17          gencies by ensuring timely and sufficient development of  
18          vaccines and other medical countermeasures (including  
19          vaccines, therapeutics, and diagnostics), as well as domes-  
20          tic manufacturing, through preparation in advance of any  
21          such public health emergency. Such Office shall be headed  
22          by a Director who has substantial relevant private sector  
23          experience and is appointed by the President, by and with  
24          the advice and consent of the Senate.”.

